| Literature DB >> 28662145 |
Hongchao Jiang1,2, Min Su1, Liyue Kui1, Hailin Huang1, Lijuan Qiu1,2, Li Li1, Jing Ma1, Tingyi Du1, Mao Fan1, Qiangming Sun2,3, Xiaomei Liu1.
Abstract
Acute bacterial meningitis is still considered one of the most dangerous infectious diseases in children. To investigate the prevalence and antibiotic resistance profiles of cerebrospinal fluid (CSF) pathogens in children with acute bacterial meningitis in Southwest China, CSF samples from 179 meningitis patients (3 days to 12 years old) with positive culture results were collected from 2012 to 2015. Isolated pathogens were identified using the Vitek-32 system. Gram stain results were used to guide subcultures and susceptibility testing. The antimicrobial susceptibility of isolates was determined using the disc diffusion method. Of the isolates, 50.8% were Gram-positive bacteria, and 49.2% were Gram-negative bacteria. The most prevalent pathogens were E. coli (28.5%), Streptococcus pneumoniae (17.8%), Staphylococcus epidermidis (10.0%), Haemophilus influenzae type b (9.5%), and group B streptococcus (7.2%). In young infants aged ≤3 months, E. coli was the organism most frequently isolated from CSF (39/76; 51.3%), followed by group B streptococcus (13/76; 17.1%) and Streptococcus pneumoniae (8/76; 10.5%). However, in young infants aged >3 months, the most frequently isolated organism was Streptococcus pneumoniae (24/103; 23.3%), followed by Staphylococcus epidermidis (18/103; 17.5%) and Haemophilus influenzae type b (16/103; 15.5%). Antimicrobial susceptibility tests indicated that for E. coli isolates, the susceptibility rates to aminoglycosides ranged from 56.8% to 100.0%, among them, amikacin was identified as the most effective against E. coli. As for cephalosporins, the susceptibility rates ranged from 29.4% to 78.4%, and cefoxitin was identified as the most effective cephalosporin. In addition, the susceptibility rates of piperacillin/tazobactam and imipenem against E. coli were 86.3% and 100%. Meanwhile, the susceptibility rates of Streptococcus pneumoniae isolates to penicillin G, erythromycin, chloramphenicol, ceftriaxone and tetracycline were 68.8%, 0.0%, 87.5%, 81.3% and 0.0%, respectively. Gentamycin, ofloxacin, linezolid and vancomycin were identified as the most effective antibiotics for Streptococcus pneumoniae, each with susceptibility rates of 100%. It was notable that other emerging pathogens, such as Listeria monocytogenes and group D streptococcus, cannot be underestimated in meningitis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28662145 PMCID: PMC5491142 DOI: 10.1371/journal.pone.0180161
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Yearly distribution of meningitis pathogens.
| Pathogens | 2012 N (%) | 2013 N (%) | 2014 N (%) | 2015 N (%) | Total N (%) |
|---|---|---|---|---|---|
| Gram-positive organisms | 91(50.8) | ||||
| 4(2.2) | 10(5.6) | 8(4.4) | 10(5.6) | 32(17.8) | |
| 2(1.1) | 5(2.9) | 6(3.3) | 5(2.9) | 18(10.0) | |
| 2(1.1) | 2(1.1) | 4(2.2) | 5(2.9) | 13(7.2) | |
| 2(1.1) | 2(1.1) | 3(1.6) | 1(0.6) | 8(4.4) | |
| 1(0.6) | 1(0.6) | 2(1.1) | 2(1.1) | 6(3.4) | |
| 1(0.6) | 1(0.6) | 2(1.1) | 1(0.6) | 5(2.9) | |
| 0(0.0) | 2(1.1) | 1(0.6) | 2(1.1) | 5(2.9) | |
| 0(0.0) | 0(0.0) | 2(1.1) | 2(1.1) | 4(2.2) | |
| Gram-negative organisms | 88(49.2) | ||||
| 5(2.9) | 13(7.3) | 15(8.4) | 18 (10.1) | 51(28.5) | |
| 2(1.1) | 5(2.9) | 4(2.2) | 6(3.3) | 17(9.5) | |
| 1(0.6) | 2(1.1) | 2(1.1) | 2(1.1) | 7(3.9) | |
| 0(0.0) | 1(0.6) | 1(0.6) | 1(0.6) | 3(1.7) | |
| 1(0.6) | 1(0.6) | 1(0.6) | 0(0.0) | 3(1.7) | |
| 0(0.0) | 0(0.0) | 2(1.1) | 1(0.6) | 3(1.7) | |
| 0(0.0) | 0(0.0) | 1(0.6) | 1(0.6) | 2(1.1) | |
| 0(0.0) | 0(0.0) | 1(0.6) | 1(0.6) | 2(1.1) | |
| Total | 21(11.7) | 45(25.1) | 55(30.7) | 58(32.5) | 179(100.0) |
Fig 1Seasonal variation in the number of confirmed meningitis cases was examined from 2012 to 2015.
A greater number of confirmed meningitis cases occurred during 2015 than occurred during any other year. The highest number of confirmed meningitis cases occurred during February 2015. The monthly prevalence of confirmed meningitis was, for the most part, lower in 2012, except for during the month of February. It was notable that the seasonal distribution indicated that the number of positive CSF cultures decreased during the rainy season (May—October) in Southwest China.
Clinical manifestations of pediatric patients with acute meningitis from 2012–2015.
| Clinical Symptoms | ≤28 days | >28days | >3months | >1ages | >3ages | Number of Patients | Occurrence (%) |
|---|---|---|---|---|---|---|---|
| Fever | 40 | 36 | 53 | 27 | 23 | 179 | 100 |
| Vomiting | 32 | 31 | 43 | 14 | 15 | 135 | 75.4 |
| Meninges irritation | 28 | 27 | 39 | 11 | 11 | 116 | 64.8 |
| Seizure | 18 | 17 | 23 | 9 | 8 | 75 | 41.8 |
| Lethargy | 16 | 15 | 21 | 7 | 6 | 65 | 36.3 |
| Headache | 3 | 3 | 6 | 8 | 7 | 27 | 15.1 |
| Stupor | 5 | 3 | 5 | 3 | 2 | 18 | 10.1 |
| Coma | 3 | 2 | 3 | 1 | 1 | 10 | 5.6 |
Frequency of bacteria isolated from patients’ CSF of different age.
| Isolate | ≤28 days | >28days | >3months | >1ages | >3ages | All ages |
|---|---|---|---|---|---|---|
| Gram-positive organisms | 91/179 (50.8) | |||||
| 4/179(2.2) | 4/179 (2.2) | 16/179 (8.8) | 5/179 (1.1) | 3/179 (0.0) | 32/179 (17.8) | |
| 0/179(0.0) | 0/179 (0.0) | 8/179 (4.4) | 3/179 (1.7) | 7/179 (3.9) | 18/179 (10.0) | |
| Group B | 6/179 (3.3) | 7/179 (3.9) | 0/179 (0.0) | 0/179 (0.0) | 0/179 (0.0) | 13/179 (7.2) |
| 5/179 (2.9) | 0/179 (0.0) | 1/179 (0.6) | 1/179 (0.6) | 1/179 (0.6) | 8/179 (4.4) | |
| Group D | 0/179 (0.0) | 0/179 (0.0) | 2/179 (1.1) | 2/179 (1.1) | 2/179 (1.1) | 6/179 (3.4) |
| 0/179 (0.0) | 1/179 (0.6) | 1/179 (0.6) | 1/179 (0.6) | 2/179 (1.1) | 5/179 (2.9) | |
| 0/179 (0.0) | 2/179 (1.1) | 1/179 (0.6) | 1/179 (0.6) | 1/179 (0.6) | 5/179 (2.9) | |
| 0/179 (0.0) | 0/179 (0.0) | 2/179 (1.1) | 2/179 (1.1) | 0/179 (0.0) | 4/179 (2.2) | |
| Gram-negative organisms | 88/179 (49.2) | |||||
| 20/179 (11.3) | 19/179 (8.8) | 11/179 (4.4) | 0/179 (0.0) | 1/179 (0.6) | 51/179 (28.5) | |
| 1/179 (0.6) | 0/179 (0.0) | 8/179 (4.4) | 8/179 (4.4) | 0/179 (0.0) | 17/179 (9.5) | |
| 1/179 (0.6) | 0/179 (0.0) | 2/179 (1.1) | 2/179 (1.1) | 2/179 (1.1) | 7/179 (3.9) | |
| 1/179 (0.6) | 2/179 (1.1) | 0/179 (0.0) | 0/179 (0.0) | 0/179 (0.0) | 3/179 (1.7) | |
| 2/179 (1.1) | 1/179 (0.6) | 0/179 (0.0) | 0/179 (0.0) | 0/179 (0.0) | 3/179 (1.7) | |
| 0/179 (0.0) | 0/179 (0.0) | 0/179 (0.0) | 0/179 (0.0) | 3/179 (1.7) | 3/179 (1.7) | |
| 0/179 (0.0) | 0/179 (0.0) | 1/179 (0.6) | 1/179 (0.6) | 0/179 (0.0) | 2/179 (1.1) | |
| 0/179 (0.0) | 0/179 (0.0) | 0/179 (0.0) | 1/179 (0.6) | 1/179 (0.6) | 2/179 (1.1) | |
| Total | 40/179 (22.4) | 36/179 (20.1) | 53/179 (29.6) | 27/179 (15.1) | 23/179 (12.8) | 179/179 (100.0) |
a/b (%), number of kind of bacteria isolated from patients’ CSF /total number of bacteria isolated from patients’ CSF (percentage of kind of bacteria).
Antimicrobial susceptibility of gram positive bacterial pathogens isolated from CSF culture.
| Antimicrobial | ||||||||
|---|---|---|---|---|---|---|---|---|
| Penicillin G | 20/32(68.8) | 0/18(0.0) | 13/13(100.0) | 0/8(0.0) | 0/6(0.0) | 0/5(0.0) | 1/5 (20.0) | 0/4(0.0) |
| Oxacillin | – | 6/18(33.3) | – | 0/8(0.0) | 0/6 (0.0) | 3/5 (60.0) | 2/5(40.0) | 3/4 (75.0) |
| Gentamicin | 32/32 (100.0) | 14/18(77.8) | – | 4/8(50.0) | 0/6 (0.0) | 5/5 (100.0) | 5/5(100.0) | 3/4 (75.0) |
| Rifampicin | – | 16/18(88.9) | – | 6/8(75.0) | 4/6 (66.7) | 5/5 (100.0) | 5/5 (100.0) | – |
| Ciprofloxacin | – | 10/18(55.6) | 9/13(69.2) | 2/8(25.0) | 4/6 (66.7) | 5/5 (100.0) | 3/5 (60.0) | 4/4 (100.0) |
| Moxifloxacin | – | 8/18(44.4) | – | 2/8(25.0) | – | 5/5 (100.0) | 3/5(60.0) | – |
| Norfloxacin | – | 10/18(55.6) | – | 1/8(12.5) | 4/6 (66.7) | 5/5 (100.0) | 3/5(60.0) | 4/4 (100.0) |
| Ofloxacin | 32/32(100.0) | 8/18(44.4) | 11/13(84.6) | 0/8(0.0) | 3/6 (50.0) | 5/5 (100.0) | 3/5(60.0) | 4/4 (100.0) |
| Levofloxacin | 28/32(87.5) | 10/18(55.6) | 10/13(76.9) | 1/8(12.5) | 3/6 (50.0) | 5/5 (100.0) | 3/5(60.0 | 4/4 (100.0) |
| Co-trimoxazole | 0/32(0.0) | 9/18(50.0) | – | 4/8(50.0) | 4/6 (66.7) | 3/5 (60.0) | 2/5(40.0) | – |
| Clindamycin | 0/32(0.0) | 11/18(61.1) | 3/13(23.1) | 3/8(37.5) | 4/6 (66.7) | 1/5 (20.0) | 2/5(40.0) | – |
| Erythromycin | 0/32(0.0) | 1/18(5.6) | 1/13(7.7) | 0/8(0.0) | 0/6 (0.0) | 1/5 (20.0) | 0/5(0.0) | 2/4 (50.0) |
| Linezolid | 32/32(100.0) | 18/18(100.0) | 13/13(100.0) | 8/8(100.0) | 6/6 (100.0) | 5/5 (100.0) | 5/5(100.0) | 4/4 (100.0) |
| Vancomycin | 32/32(100.0) | 18/18(100.0) | 13/13(100.0) | 8/8(100.0) | 5/6 (83.3) | 5/5 (100.0) | 5/5 (100.0) | 4/4 (100.0) |
| Chloramphenicol | 28/32(87.5) | 15/18(83.3) | 11/13(84.6) | 7/8(87.5) | 4/6 (66.7) | 3/5 (60.0) | 4/5 (80.0) | – |
| Tetracycline | 0/32(0.0) | 6/18(33.3) | 0/13(0.0) | 4/8(50.0) | 1/6 (16.7) | 1/5 (20.0) | 3/5 (60.0) | – |
| Ampicillin | – | 0/18(0.0) | 13/13(100.0) | 0/8(0.0) | 3/6 (50.0) | 0/5 (0.0) | 1/5 (20.0) | 2/4 (50.0) |
| Amoxicillin+clavulanate | – | 5/18(27.7) | – | 2/8(25.0) | – | 2/5 (40.0) | 2/5 (40.0) | – |
| Ceftriaxone | 26/32(81.3) | – | 13/13(100.0) | – | 0/6 (0.0) | – | – | 4/4 (100.0) |
| Meropenem | 24/32(75.0) | – | 13/13(100.0) | – | – | – | – | – |
| Azithromycin | – | 0/18(0.0) | – | 0/8(0.0) | – | 0/5 (0.0) | 0/5 (0.0) | – |
| Clarithromycin | – | 3/18(16.6) | – | 2/8(25.0) | – | 4/5 (80.0) | 3/5 (60.0) | – |
| Total | 32 | 18 | 13 | 8 | 6 | 5 | 5 | 4 |
a/b (%), number susceptible/number tested (percentage susceptible).
Antibiotics were not tested against all organisms with dash (–).
Antimicrobial susceptibility of gram negative bacterial pathogens isolated from CSF culture.
| Antimicrobial | ||||||||
|---|---|---|---|---|---|---|---|---|
| Ampicillin | 2/51(3.9) | 1/17(5.8) | 0/7(0.0) | 0/3(0.0) | – | 0/3(0.0) | – | – |
| Piperacillin | 8/51(15.7) | – | – | – | 2/3(66.7) | – | 1/2(50.0) | 1/2(50.0) |
| Ampicillin/sulbactam | 15/51(29.4) | – | – | 3/3(100.0) | 1/3(33.3) | 2/3(66.6) | – | – |
| Piperacillin/Tazobactam | 44/51(86.3) | – | – | 3/3(100.0) | 3/3(100.0) | – | 2/2(100.0) | 1/2(50.0) |
| Cefoperazone | 15/51(29.4) | 6/17(35.2) | 3/7 (42.8) | 1/3(33.3) | – | 2/3(66.6) | 0/2(0.0) | 0/2(0.0) |
| Cefuroxime | 22/51(43.1) | 14/17(82.4) | 2/7(28.5) | 1/3(33.3) | – | 1/3(33.3) | 0/2(0.0) | 0/2(0.0) |
| Ceftazidime | 34/51(66.6) | 14/17(82.4) | 3/7 (42.8) | 1/3(33.3) | 2/3(66.7) | 2/3(66.6) | 0/2(0.0) | 0/2(0.0) |
| Ceftriaxone | 22/51(43.1) | 14/17(82.4) | 2/7 (28.5) | 1/3(33.3) | 0/3(0.0) | 1/3(33.3) | 0/2(0.0) | 0/2(0.0) |
| Cefepime | 34/51(66.6) | 16/17(94.1) | 4/7 (57.1) | 2/3(66.6) | 2/3(66.7) | 3/3(100.0) | 0/2(0.0) | 0/2(0.0) |
| Cefoxitin | 44/51(78.4) | – | – | 1/3(33.3) | – | – | – | – |
| Aztreonam | 25/51(49.0) | – | – | – | 2/3(66.7) | – | – | – |
| Imipenem | 51/51(100.0) | 17/17(100.0) | 7/7(100.0) | 3/3(100.0) | 3/3(100.0) | 3/3(100.0) | 2/2(100.0) | 2/2(100.0) |
| Meropenem | 51/51(100.0) | 17/17(100.0) | 7/7(100.0) | 3/3(100.0) | 3/3(100.0) | 3/3(100.0) | 2/2(100.0) | 2/2(100.0) |
| Amikacin | 51/51(100.0) | 4/17(23.5) | 7/7(100.0) | 1/3(33.3) | 3/3(100.0) | 3/3(100.0) | 1/2(50.0) | 1/2(50.0) |
| Gentamicin | 30/51(58.8) | 15/17(88.2) | 6/7(85.7) | 1/3(33.3) | 3/3(100.0) | – | 1/2(50.0) | 1/2(50.0) |
| Tobramycin | 38/51(74.5) | – | 6/7(85.7) | – | 3/3(100.0) | – | 0/2(0.0) | 0/2(0.0) |
| Ciprofloxacin | 32/51(62.7) | 16/17(94.1) | – | 2/3(66.6) | 3/3(100.0) | 3/3(100.0) | 1/2(50.0) | 1/2(50.0) |
| Levofloxacin | 30/51(58.8) | – | 5/7(71.4) | 2/3(66.6) | 3/3(100.0) | 3/3(100.0) | 1/2(50.0) | 1/2(50.0) |
| Norfloxacin | 29/51(56.8) | – | 6/7(85.7) | – | – | 3/3(100.0) | – | – |
| Co-trimoxazole | 16/51(31.4) | 4/17(23.5) | 1/7(14.2) | 1/3(33.3) | – | – | 0/2(0.0) | 0/2(0.0) |
| Chloramphenicol | 45/51(88.2) | 17/17(100.0) | 1/7(14.2) | 3/3(100.0) | 1/3(33.3) | – | 1/2(50.0) | 0/2(0.0) |
| Minocycline | 38/51(74.5) | – | – | – | – | 3/3(100.0) | – | – |
| Total | 51 | 17 | 7 | 3 | 3 | 3 | 2 | 2 |
a/b (%), number susceptible/number tested (percentage susceptible).
Antibiotics were not tested against all organisms with dash (–).